SG Americas Securities’s GALENA BIOPHARMA INC COM RXII Stock Holding History

SG Americas Securities’s Portfolio RXII Stock Details RXII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-34,197	Closed	-$12K	–	3735
2016 Q3	$12K	Buy	+34,197	New	+$12K	﹤0.01%	3273
2015 Q2	–	Sell	-33,074	Closed	-$46K	–	3050
2015 Q1	$46K	Buy	+33,074	New	+$46K	﹤0.01%	2377
2014 Q4	–	Sell	-29,559	Closed	-$61K	–	3568
2014 Q3	$61K	Sell	29,559 -2,007	-6%	-$4.14K	﹤0.01%	2464
2014 Q2	$97K	Buy	+31,566	New	+$97K	﹤0.01%	2345
2013 Q4	–	Sell	-32,243	Closed	-$73K	–	3424
2013 Q3	$73K	Buy	32,243 +20,736	+180%	+$46.9K	﹤0.01%	2733
2013 Q2	$26K	Buy	+11,507	New	+$26K	﹤0.01%	2225

SG Americas Securities's RXII Position: Q4 2016 in Review

SG Americas Securities sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 34,197 shares — an estimated $12K sold.

SG Americas Securities first reported a position in RXII in Q2 2013 and held it in 6 quarters. The position peaked at $97K in Q2 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

SG Americas Securities reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
SG Americas Securities sold 34,197 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $12K.
SG Americas Securities first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 6 quarters.
SG Americas Securities's GALENA BIOPHARMA INC COM position peaked at $97K in Q2 2014.
0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on SG Americas Securities's 13F filing for Q4 2016, filed 8 Feb 2017.